Header Logo

Connection

KEVIN GAREY to Antifungal Agents

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Antifungal Agents.
KEVIN GAREY
Connection Strength
4.601
Antifungal Agents
  1. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 09; 14:58-64.
    View in: PubMed
    Score: 0.498
  2. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
    View in: PubMed
    Score: 0.413
  3. Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr; 349(4):316-20.
    View in: PubMed
    Score: 0.407
  4. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
    View in: PubMed
    Score: 0.343
  5. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1086-96.
    View in: PubMed
    Score: 0.337
  6. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun; 56(6):3239-43.
    View in: PubMed
    Score: 0.329
  7. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
    View in: PubMed
    Score: 0.313
  8. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007 Aug; 16(8):919-27.
    View in: PubMed
    Score: 0.239
  9. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May; 29(5):557-62.
    View in: PubMed
    Score: 0.233
  10. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 01; 43(1):25-31.
    View in: PubMed
    Score: 0.220
  11. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006 May; 49(3):226-31.
    View in: PubMed
    Score: 0.219
  12. Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
    View in: PubMed
    Score: 0.178
  13. Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct; 41(10):1207-1213.
    View in: PubMed
    Score: 0.170
  14. Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. Pharmacotherapy. 2001 Jul; 21(7):855-60.
    View in: PubMed
    Score: 0.157
  15. In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. J Clin Microbiol. 2018 08; 56(8).
    View in: PubMed
    Score: 0.128
  16. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
    View in: PubMed
    Score: 0.096
  17. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
    View in: PubMed
    Score: 0.095
  18. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
    View in: PubMed
    Score: 0.059
  19. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
    View in: PubMed
    Score: 0.057
  20. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci. 2003 May; 44(5):2112-7.
    View in: PubMed
    Score: 0.045
  21. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep; 21(9):1107-14.
    View in: PubMed
    Score: 0.040
  22. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15; 60(6):892-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.